Drug interactions
Elacestrant + Lorlatinib
Severity: Major
Elacestrant and Lorlatinib: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Lorlatinib induces CYP3A and can lower elacestrant exposure, a CYP3A4 substrate, potentially reducing its efficacy. Elacestrant labeling advises avoiding strong and moderate CYP3A inducers.
What this interaction means in plain words
Elacestrant and Lorlatinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Elacestrant belongs to Oncology; Lorlatinib belongs to Oncology.
Why it happens
Lorlatinib induces CYP3A4, increasing elacestrant clearance.
What to do
Avoid concomitant use and select an alternative to one of the agents. If unavoidable, monitor for reduced disease control.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Elacestrant and Lorlatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Lorlatinib
- Amobarbital + Lorlatinib Contraindicated
- Apalutamide + Lorlatinib Contraindicated
- Butabarbital + Lorlatinib Contraindicated
- Carbamazepine + Lorlatinib Contraindicated
- Enzalutamide + Lorlatinib Contraindicated
- Fosphenytoin + Lorlatinib Contraindicated
Other interactions of Elacestrant
Frequently asked questions
Can I take Elacestrant with Lorlatinib?
MediHelp rates the interaction as major. Elacestrant and Lorlatinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Lorlatinib induces CYP3A and can lower elacestrant exposure, a CYP3A4 substrate, potentially reducing its efficacy. Elacestrant labeling advises avoiding strong and moderate CYP3A inducers.
How serious is the interaction between Elacestrant and Lorlatinib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid concomitant use and select an alternative to one of the agents. If unavoidable, monitor for reduced disease control.
What other medicines interact with Lorlatinib?
MediHelp also lists interactions of Lorlatinib with, for example, Amobarbital, Apalutamide, Butabarbital. The full list is on the Lorlatinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
